Accelerating life-extending
therapies, treatments and cures
for all myeloma patients.

THE STATE OF MULTIPLE MYELOMA

The myeloma patient community
has no time for business as usual.

Multiple myeloma is a highly heterogenous bone marrow cancer that requires a multitude of drugs to effectively treat every patient. About 30,000 Americans are diagnosed each year, and over 10,000 will die of the disease annually. However, over the last two decades, we’ve made advances in science and technology that were unimaginable a few short years ago, finally putting the cure within reach. As leaders in the industry, the time to use our means, savvy, and foresight to drive the innovation needed us to win the fight against cancer once and for all is now.

Our People


Investment Strategy


We created the Myeloma Investment Fund to leverage the MMRF’s formidable assets and advance new therapies for our patients — while generating a return to reinvest in even more research

Peter Kosa Ph.D, Managing Director of The Myeloma Investment Fund